Table 1.
Patients’ clinical profiles.
| Patients | Age (years) | Sex | Disease | SFR (mL/ min) |
Focus Score |
ANA | SSA | SSB |
|---|---|---|---|---|---|---|---|---|
| 235 | 40 | F | SC | 0.130 | 0 | − | + | − |
| 150 | 44 | F | SC | 0.150 | 0 | + | − | − |
| 252 | 46 | F | SC | 0.110 | 0 | − | − | − |
| 255 | 47 | F | SC | 0.020 | 0 | − | − | + |
| 257 | 49 | F | SC | 0.048 | 0 | − | − | − |
| 251 | 51 | F | SC | 0.190 | 0 | + | + | − |
| 236 | 52 | F | SC | 0.047 | 0 | − | − | − |
| 264 | 52 | F | SC | 0.380 | 0 | − | − | − |
| 265 | 54 | F | SC | 0.210 | 0 | − | − | − |
| 215 | 55 | F | SC | 0.012 | 0 | − | − | − |
| 229 | 55 | F | SC | 0.020 | 0 | − | − | − |
| 243 | 57 | F | SC | 0.002 | 0 | − | − | − |
| 220 | 57 | F | SC | 0.070 | 0 | − | − | − |
| 259 | 67 | F | SC | 0.152 | 0 | − | − | − |
| 242 | 68 | F | SC | 0.280 | 0 | + | − | − |
| 239 | 73 | F | SC | 0.048 | 0 | − | − | − |
| 261 | 70 | M | SC | 0.080 | 0 | + | − | − |
| 246 | 72 | M | SC | 0.312 | 0 | − | − | − |
| 262 | 75 | M | SC | 0.400 | 0 | − | + | − |
| 248 | 76 | M | SC | 0.002 | 0 | − | − | − |
| 247 | 36 | F | pSS | 0.134 | 1 | + | − | + |
| 241 | 48 | F | pSS | 0.176 | 5 | + | + | − |
| 227 | 50 | F | pSS | 0.030 | 9 | + | + | − |
| 254 | 53 | F | pSS | 0.007 | 3 | + | − | − |
| 226 | 58 | F | pSS | 0.020 | 2 | − | − | − |
| 249 | 59 | F | pSS | 0.054 | 1 | + | + | − |
| 258 | 69 | F | pSS | 0.104 | 1 | + | − | − |
| 260 | 66 | M | pSS | 0.080 | 0 | − | + | − |
| 263 | 61 | F | pSS | 0.068 | 1 | − | − | − |
Summary of patient profiles of the individuals in this study. SC: sicca. control, pSS: primary Sjögren’s Syndrome, SFR: unstimulated saliva flow rate, Focus score is based on a scale of 1–9 where 9 represents severe in, ANA: Antinuclear antibody, SSA: anti-SSA/Ro, SSB: anti-SSB/La.